Annual reports

Sohlberg E, Malmberg KJ (2025)
The innate power of natural killer cells in cancer therapy
Nat Med (in press)
DOI 10.1038/s41591-025-03712-9, PubMed 40355615

Trachsel-Moncho L, Mathai BJ, Veroni C, Simonsen A (2025)
SNX10 at the crossroad of endocytosis and piecemeal mitophagy
Autophagy, 1-3 (in press)
DOI 10.1080/15548627.2025.2499641, PubMed 40327657

Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK (2025)
Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50
ESMO Open, 10 (5), 105073 (in press)
DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908

Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS (2025)
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Clin Cancer Res, 31 (10), 1943-1955
DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050

Sohlberg E, Malmberg KJ (2025)
The innate power of natural killer cells in cancer therapy
Nat Med (in press)
DOI 10.1038/s41591-025-03712-9, PubMed 40355615

Kotkowska ZK, Haunerdinger V, Waeckerle-Men Y, Kolm-Djamei I, Duda A, Hausammann L, Schineis P, Fischer H, Sella F, Li N, Selbo PK, Høgset A, Kündig TM, Halin C, Johansen P (2025)
Inflammatory cutaneous reactions with systemic CD8⁺ T-cell responses upon photochemical internalization of antigens in mice
J Invest Dermatol (in press)
DOI 10.1016/j.jid.2025.04.020, PubMed 40348329